BioSpace News Archive

Surgalign Holdings, Inc. today announced further advancement in the commercialization of its HOLO Portal™ surgical guidance system.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company’s IL-12 gene-mediated immunotherapy.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced hat the Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report updating the previous Hemophilia A assessment of the comparative clinical effectiveness and value of ROCTAVIAN ™ (valoctocogene roxaparvovec).

Todos Medical, Ltd. reported the preprint in ResearchGate of a case study entitled “Consequences of Microclot Pathophysiology Underlying Long COVID Improved with Tollovid Supplementation.”

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today commented on the Centers for Medicare and Medicaid Services (“CMS”) development of new codes for the diagnosis and tracking of refractory angina.

Microbot Medical Inc., which continues to build a network of global leaders in the endovascular interventional space for the LIBERTY® Robotic System, announced that Vincent Vidal, M.D., PhD, has joined its Scientific Advisory Board.

Teleflex Incorporated announced that Dr. Magnus Settergren*, Asssociate Professor at the Karolinska Institutet, Interventional Cardiologist at Karolinska University Hospital is scheduled to present at a Teleflex-sponsored Training Pavilion at the Transcatheter Cardiovascular Therapeutics conference.

Caris Life Sciences® announced that Russ Denton has joined the company as Senior Vice President, General Counsel and Secretary, and will lead Caris’ legal and corporate governance efforts.

BioJiva, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today reported data from its completed multicenter, randomized, double-blind, placebo-controlled pilot Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

BVI, a diversified global ophthalmic device company, today announced certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹.